<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057575</url>
  </required_header>
  <id_info>
    <org_study_id>PG324-CS201</org_study_id>
    <nct_id>NCT02057575</nct_id>
  </id_info>
  <brief_title>Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its
      individual components in patients with open angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diurnal Intraocular Pressure</measure>
    <time_frame>Day 29</time_frame>
    <description>Mean diurnal intraocular pressure across subjects within treatment group at Day 29</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Intraocular Pressure</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>Mean intraocular pressure across subjects within treatment group at each post-treatment timepoint on Day 8, Day 15, Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Intraocular Pressure</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>Mean change from diurnally adjusted baseline intraocular pressure at each timepoint on Day 8, Day 15, Day 29.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>PG324 Ophthalmic Solution 0.01%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PG324 Ophthalmic Solution 0.01%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PG324 Ophthalmic Solution 0.02%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PG324 Ophthalmic Solution 0.02%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Netarsudil (AR-13324) Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Netarsudil (AR-13324) Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost Ophthalmic Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG324 Ophthalmic Solution 0.01%</intervention_name>
    <description>1 drop daily (evening)</description>
    <arm_group_label>PG324 Ophthalmic Solution 0.01%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG324 Ophthalmic Solution 0.02%</intervention_name>
    <description>1 drop daily (evening)</description>
    <arm_group_label>PG324 Ophthalmic Solution 0.02%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil (AR-13324) Ophthalmic Solution</intervention_name>
    <description>1 drop daily (evening)</description>
    <arm_group_label>Netarsudil (AR-13324) Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost Ophthalmic Solution</intervention_name>
    <description>1 drop daily (evening)</description>
    <arm_group_label>Latanoprost Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or greater.

          -  Diagnosis of open angle glaucoma or ocular hypertension

          -  Corrected visual acuity in each eye equivalent to 20/200

          -  Able and willing to give signed informed consent and follow study instructions.

          -  Additional protocol-specific criteria may apply

        Exclusion Criteria:

          -  Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure,
             or narrow angles.

          -  Known hypersensitivity to any component of the formulation (benzalkonium chloride,
             etc.), latanoprost, or to topical anesthetics.

          -  Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s)

          -  Refractive surgery in study eye(s)

          -  Ocular trauma within the six months prior to screening, or ocular surgery or laser
             treatment within the three months prior to screening.

          -  Clinically significant ocular disease (e.g. corneal edema, uveitis, severe
             keratoconjunctivitis sicca) which might interfere with the study, including
             glaucomatous damage so severe that washout of ocular hypotensive medications for one
             month is not judged safe

          -  Clinically significant abnormalities (as determined by the investigator) in laboratory
             tests at screening.

          -  Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia
             gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere
             with the study.

          -  Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control. An adult woman is considered
             to be of childbearing potential unless she is one year post-menopausal or three months
             post-surgical sterilization. All females of childbearing potential must have a
             negative urine pregnancy test result at the screening examination and must not intend
             to become pregnant during the study.

          -  Additional protocol-specific criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Ramirez, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aerie Clinical Operations</name>
      <address>
        <city>Bedminster</city>
        <state>New Jersey</state>
        <zip>07921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <disposition_first_submitted>July 9, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2015</disposition_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>AR13324</keyword>
  <keyword>PG324</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

